For Institutions
About
Hotgen's affiliated company Hangzhou Aorui Biotechnology Co., Ltd. has obtained the domestic Class III medical device registration certificate. The product is a gene methylation detection kit, suitable for the in vitro qualitative detection of methylation of multiple genes in human plasma, primarily used for assisting in the diagnosis of suspected primary liver cancer
Hanwei Electronics Group Corporation reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 1,702.2 million compared to CNY 1,569.77 million a year ago. Net income was CNY 84.84 million compared to CNY 79.79 million a year ago.Basic earnings per share from continuing operations was CNY 0.26 compared to CNY 0.24 a year ago. Diluted earnings per share from continuing operations was CNY 0.26 compared to CNY 0.24 a year ago.
According to the Zhitong Finance APP, Zhenhua Chemical disclosed its third-quarter report for 2025. The company achieved revenue of 3.217 billion yuan in the first three quarters, a year-on-year increase of 7.47%; net profit attributable to the parent company was 410 million yuan, a year-on-year increase of 12.56%; net profit excluding non-recurring gains and losses was 411 million yuan, a year-on-year increase of 11.93%; basic earnings per share were 0.58 yuan
Beijing Hotgen Biotech Q3 net loss at 25.0 million yuan
According to the Zhitong Finance APP, Hotgen disclosed its third-quarter report for 2025. The company achieved revenue of 310 million yuan in the first three quarters, a year-on-year decrease of 19.8%; the net loss attributable to shareholders of the listed company was 109 million yuan; the net profit excluding non-recurring items was a loss of 148 million yuan; basic earnings per share were -1.23 yuan
